|Bid||740.20 x 0|
|Ask||740.20 x 0|
|Day's range||720.40 - 754.50|
|52-week range||475.45 - 834.50|
|Beta (5Y monthly)||0.26|
|PE ratio (TTM)||37.06|
|Forward dividend & yield||9.35 (1.35%)|
|Ex-dividend date||16 Aug 2021|
|1y target est||N/A|
A question on the minds of many investors right now is how economic uncertainty will continue to affect large cap companies, such as Novo Nordisk A/S (CPH:NOVO...
Prosper Junior Bakiny (Novo Nordisk): For the past several decades, Novo Nordisk has been a leader in the market for diabetes drugs. As of February 2022, the company held a 30.5% share of the diabetes care market, an increase from the 29.3% slice of the pie it had in February 2021. Novo Nordisk's dominance in this therapeutic area is one reason it has outperformed the broader market in each of the past one, five, 10, and 20 years.
Prothena beats on earnings and revenues in the first quarter of 2022. The company's progress with its AD pipeline is encouraging.